Praxair gets Canadian approval for sale of Noxivent nitric oxide


Praxair Canada has secured approval for the sale of its Noxivent brand of inhaled nitric oxide.

Earlier this year, Praxair acquired NOxBOX, a company that specialises in the manufacture of inhaled gas delivery and monitoring instruments for the medical market.

Praxair Canada's Noxivent inhaled nitric oxide, in conjunction with ventilatory support and other appropriate agents, is indicated to treat term and late pre-term (=34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension.

"Approval will enable us to provide our Canadian hospital customers with a comprehensive respiratory offering in a cost-effective manner."

The inhaled nitric oxide improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

Praxair Canada president Sean Durbin said: "With this approval from Health Canada, we will pair the Noxivent product with the NOxBOXi delivery system, enabling us to provide our Canadian hospital customers with a comprehensive respiratory offering in a cost-effective manner.

"Our customers have been looking for choices in the marketplace and we are pleased to be able to deliver."

It is reported that Noxivent gas will be available for sale and use in Canada in 800ppm and 100ppm concentrations.

It is reported that inhaled nitric oxide requires patient monitoring and management to help avoid patient complications due to toxic levels of nitrogen dioxide and rebound pulmonary hypertension associated with weaning from inhaled nitric oxide.

The NOxBOXi delivery device will offer intelligent nitric oxide delivery with precise real-time monitoring of nitric oxide, nitrogen dioxide, and oxygen through a touch screen with step-by-step guided interface to enable ease-of-use.